Bayer AG said on Tuesday it will scrap a nearly $1 billion project to produce the chemical dicamba in the United States, but said the move is unrelated to a federal court decision that blocked sales of weed killers based on the product.
Could the least exciting bit of Elon Musk’s empire end up being the most transformative? …read more […]
In 2019, this was a $51 billion market…
And right now, demand has never been higher.
In the month of May, sales shot up 170%.
One firm just reported a 1,000% increase in bookings in April.
And in my newest Trade Talk Tuesdays video, I tell you the best way to play it.
The extra trade to make on Tuesday, June 23, is revealed below…
For full instructions on how to play picks like this, join me in The War Room!
The post Make This Exact Trade on Tuesday, June 23 appeared first on Investment U. …read more […]
When I was a kid, my grandfather was fond of reminding me that “a bird in the hand is worth two in the bush.”
What does that mean?
That something you already possess is more valuable than something you think might be better but have a less certain chance of you actually getting.
When it comes to valuing automobile manufacturers, investors today could use a lesson from my grandfather. Let me explain…
Market capitalization shows that today’s investors value hypothetical cash flow much more highly than cash flow that many companies are already producing.
Let me show you what I mean…
A Futuristic Play Already Valued …read more […]
Tesla Inc has signed a three-year pricing deal with Japan’s Panasonic Corp relating to the manufacture and supply of lithium-ion battery cells at the Gigafactory in Nevada, the electric carmaker disclosed in a filing on Tuesday.
U.S. prosecutors on Tuesday said a former Green Beret and his son, wanted by Japan for helping former Nissan Motor Co boss Carlos Ghosn flee the country, were advancing a “flawed” interpretation of Japanese law to fight their extradition.
The last five years have been one unstoppable ride to the summit for chipmaker Advanced Micro Devices (AMD). Simultaneously closing the gap between its traditionally bigger rivals, Intel and Nvidia, and itself, the CPU/GPU maker is now most definitely a force to be reckoned with.Following an investor call with the company, Nomura analyst David Wong sees no reason to change tack when considering AMD as an investment.The 5-star analyst has a Buy rating on AMD shares to go along with a $64 price target. The implication for investors? Potential upside of 18% from current levels. (To watch Wong’s track record, …read more […]
Hopes of a Covid-19 treatment, additional stimulus and a faster than anticipated economic recovery powered stocks to their third straight session of gains earlier Tuesday. …read more […]
Southwest Airlines Co said on Tuesday it will continue to limit bookings on its flights until at least September to maintain space between passengers.
In this article we will check out the progression of hedge fund sentiment towards Smith & Wesson Brands, Inc. (NASDAQ:AOBC) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their […] …read more […]
As the largest mobile chipmaker in the world, Qualcomm (QCOM) is expected to be one of the main beneficiaries of the upcoming 5G cycle.However, there’s a particular segment of Qualcomm’s business that gets less attention, but has gradually become more prominent.Susquehanna analyst Christopher Rolland recently spoke to Qualcomm’s resident RF expert, to discuss an “often-misunderstood piece of Qualcomm’s business model.”Qualcomm’s RF front end business – the components that turn the information into radio signals – grew by 50% year-over-year in the first quarter. Rolland estimates the segment makes up 10% of Qualcomm’s overall business, amounting to what is now …read more […]
(Bloomberg) — Oracle Corp. reported sales that fell short of analysts’ estimates, signaling that the coronavirus pandemic and recession have spurred a pullback in corporate spending on information technology.Revenue declined about 6.3% to $10.4 billion in the period ended May 31, the Redwood City, California-based company said Tuesday in a statement. Analysts, on average, projected $10.7 billion, according to data compiled by Bloomberg. Shares declined about 4% in extended trading after the results.Chief Executive Officer Safra Catz and Executive Chairman Larry Ellison have sought to renew growth at Oracle, the world’s second-largest software maker. The shift to cloud computing caught …read more […]
Risk appetite found new life on Tuesday on a record rebound in U.S. retail sales, fresh support from the Federal Reserve and Bank of Japan, and upbeat trial results for a COVID-19 treatment, driving global equity markets higher and boosting the dollar.
Vaccine maker Moderna (MRNA) is on everyone’s radar, with shares rocketing from the $20 level in January to over $60 today. Moderna stock got another small boost yesterday after the inventor of a leading coronavirus vaccine proposal was reported to be nearing a deal to sell its vaccine to Israel. Citing unnamed sources within the Israeli Health Ministry, news site Ynet.com noted that with Phase 2 clinical trials of the vaccine — mRNA-1273 — nearly complete, Israel is already “in final negotiations” to buy supplies of the vaccine for distribution to its populace. Which is great news, but here’s the …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
